부산대학교 도서관

The data on the use of dual biologics are scant, but a topic of current interest. In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented. Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use. This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature. [ABSTRACT FROM AUTHOR]